Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized Phase 2 study of Imprime PGG and durvalumab combination in head and neck squamous cell carcinoma

Trial Profile

A randomized Phase 2 study of Imprime PGG and durvalumab combination in head and neck squamous cell carcinoma

Planning
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2018

At a glance

  • Drugs Durvalumab (Primary) ; PGG-glucan (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Biothera
  • Most Recent Events

    • 16 Sep 2018 New trial record
    • 05 Sep 2018 According to a Biothera media release, the company expects to initiate the study in the second half of 2018. The trial will be conducted at several clinical sites, including Sanford Health, USA. Completion of patient enrollment is expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top